-
公开(公告)号:US5219874A
公开(公告)日:1993-06-15
申请号:US763304
申请日:1991-09-20
IPC分类号: A61K31/415 , A61K31/425 , A61P7/02 , A61P9/00 , A61P9/10 , A61P9/12 , C07D263/26 , C07D403/04 , C07D405/04 , C07D417/04
CPC分类号: C07D403/04 , C07D263/26 , C07D417/04
摘要: The invention concerns novel 1,3-dioxane alkenoic acid derivatives of the formula I ##STR1## wherein: n is the integer 1 or 2;Y is methyleneoxy, vinylene or ethylene;A.sup.1 is (1-6C)alkylene;R.sup.1 is a group of the formula R.sup.2.A.sup.2 --, in which:R.sup.2 is phenyl unsubstituted or bearing up to three substituents which are independently selected from (1-6C)alkyl, (1-6C)alkoxy, (2-6C)alkanoyl, (1-6C)alkylthio, (1-6C)alkylsulphonyl, halogeno, trifluoromethyl, nitro and cyano;A.sup.2 is a direct bond to R.sup.2 or a group of the formula --W--C(R.sup.4)(R.sup.5)-- wherein W is oxygen, methylene or a direct bond to R.sup.2, and R.sup.4 and R.sup.5 are independently (1-4C)alkyl;Q is a heterocyclyl group selected from thiazol-5-yl and imidazol-5-yl, the latter being unsubstituted or bearing a (1-12C)alkyl group at the 1-position of the imidazole ring; andR.sup.3 is hydroxy, a physiologically acceptable alcohol residue, or (1-4C)alkanesulphonamido;or a pharmaceutically acceptable salt thereof. The compounds are thromboxane A.sub.2 antagonists and inhibitors of thromboxane A.sub.2 synthase.
摘要翻译: 本发明涉及式I的新型1,3-二恶烷烯酸衍生物,其中:n是整数1或2; Y是亚甲氧基,亚乙烯基或亚乙基; A1为(1-6C)亚烷基; R1是式R2.A2-的基团,其中:R2是未取代的或最多带有三个独立地选自(1-6C)烷基,(1-6C)烷氧基,(2-6C)烷酰基的取代基的苯基 ,(1-6C)烷硫基,(1-6C)烷基磺酰基,卤代,三氟甲基,硝基和氰基; A2是与R2或式-W-C(R4)(R5) - 的基团的直接键合,其中W是氧,亚甲基或与R2的直接键合,R4和R5独立地是(1-4C)烷基; Q是选自噻唑-5-基和咪唑-5-基的杂环基,后者是未取代的或在咪唑环的1位带有(1-12C)烷基; 和R3是羟基,生理上可接受的醇残基或(1-4C)烷基磺酰胺基; 或其药学上可接受的盐。 化合物是凝血恶烷A2拮抗剂和血栓烷A2合酶抑制剂。
-
公开(公告)号:US5410064A
公开(公告)日:1995-04-25
申请号:US36304
申请日:1993-03-24
申请人: Alan W. Faull , Keith Russell , William J. Watkins
发明人: Alan W. Faull , Keith Russell , William J. Watkins
IPC分类号: A61K31/415 , A61K31/425 , A61P7/02 , A61P9/00 , A61P9/10 , A61P9/12 , C07D263/26 , C07D403/04 , C07D405/04 , C07D417/04 , C07D263/38
CPC分类号: C07D403/04 , C07D263/26 , C07D417/04
摘要: The invention concerns novel 1,3-dioxane alkenoic acid derivatives of the formula I ##STR1## wherein: n is the integer 1 or 2; Y is methyleneoxy, vinylene or ethylene;A.sup.1 is (1-6C)alkylene;R.sup.1 is a group of the formula R.sup.2.A.sup.2 -, in which:R.sup.2 is phenyl unsubstituted or bearing up to three substituents which are independently selected from (1-6C)alkyl, (1-6C)alkoxy, (2-6C)alkanoyl, (1-6C)alkylthio, (1-6C)alkylsulphonyl, halogeno, trifluoromethyl, nitro and cyano;A.sup.2 is a direct bond to R.sup.2 or a group of the formula --W--C(R.sup.4)(R.sup.5)-- wherein W is oxygen, methylene or a direct bond to R.sup.2, and R.sup.4 and R.sup.5 are independently (1-4C)alkyl;Q is a heterocyclyl group selected from thiazol-5-yl and imidazol-5-yl, the latter being unsubstituted or bearing a (1-12C)alkyl group at the 1-position of the imidazole ring; andR.sup.3 is hydroxy, a physiologically acceptable alcohol residue, or (1-4C)alkanesulphonamido;or a pharmaceutically acceptable salt thereof. The compounds are thromboxane A.sub.2 antagonists and inhibitors of thromboxane A.sub.2 synthase, and are useful on the treatment of a variety of diseases in which thromboxane A.sub.2 is involved, such as is ischaemic heart disease, cerebrovascular disease and peripheral vascular disease. The invention also includes processes for the manufacture and use of the compounds, and pharmaceutical compositions containing them.
摘要翻译: 本发明涉及式I的新型1,3-二恶烷烯酸衍生物,其中:n是整数1或2; Y是亚甲氧基,亚乙烯基或亚乙基; A1为(1-6C)亚烷基; R1是式R2.A2-的基团,其中:R2是未取代的或最多带有三个独立地选自(1-6C)烷基,(1-6C)烷氧基,(2-6C)烷酰基的取代基的苯基 ,(1-6C)烷硫基,(1-6C)烷基磺酰基,卤代,三氟甲基,硝基和氰基; A2是与R2或式-W-C(R4)(R5) - 的基团的直接键合,其中W是氧,亚甲基或与R2的直接键合,R4和R5独立地是(1-4C)烷基; Q是选自噻唑-5-基和咪唑-5-基的杂环基,后者是未取代的或在咪唑环的1位带有(1-12C)烷基; 和R3是羟基,生理上可接受的醇残基或(1-4C)烷基磺酰胺基; 或其药学上可接受的盐。 化合物是凝血恶烷A2拮抗剂和凝血恶烷A2合酶抑制剂,可用于治疗血栓素A2涉及的多种疾病,例如缺血性心脏病,脑血管病和外周血管病。 本发明还包括用于制备和使用化合物的方法以及含有它们的药物组合物。
-
公开(公告)号:US5248780A
公开(公告)日:1993-09-28
申请号:US951760
申请日:1992-09-25
IPC分类号: C07D405/04 , C07D405/14
CPC分类号: C07D405/04 , C07D405/14
摘要: The invention concerns novel, pharmaceutically useful 1,3-dioxane alkenoic acid derivatives of the formula I containing a pyridyl moiety at position 4 of the dioxane ring and in which the groups at positions 2, 4 and 5 have cis-relative stereochemistry, X is hydrogen, alkoxy or hydroxy, Y is vinylene, n is 1 or 2, A.sup.1 is alkylene, R.sup.1 is a variety of substituents defined hereinafter, and R.sup.2 is hydroxy, a physiologically acceptable alcohol residue or alkanesulphonamido, and the pharmaceutically acceptable salts thereof. The invention also includes processes for the manufacture and use of the acid derivatives as well as pharmaceutical compositions for therapeutic use in one or more of a variety of diseases such as ischaemic heart disease, cerebrovascular disease, asthmatic disease and/or inflammatory disease.
摘要翻译: 本发明涉及式I的新型药学上有用的1,3-二烷基链烯酸衍生物,其在二恶烷环的第4位含有吡啶基部分,其中第2,4和5位的基团具有顺式相对立体化学,X是 氢,烷氧基或羟基,Y是亚乙烯基,n是1或2,A1是亚烷基,R1是下文定义的各种取代基,R2是羟基,生理上可接受的醇残基或烷基磺酰氨基,及其药学上可接受的盐。 本发明还包括用于制备和使用酸衍生物的方法以及用于治疗用于一种或多种疾病如缺血性心脏病,脑血管疾病,哮喘病和/或炎性疾病的药物组合物。
-
公开(公告)号:US06833387B1
公开(公告)日:2004-12-21
申请号:US09889516
申请日:2001-10-02
申请人: Alan W. Faull , Jason Kettle
发明人: Alan W. Faull , Jason Kettle
IPC分类号: A61K3138
CPC分类号: A61K31/541 , A61K31/404 , A61K31/41 , A61K31/4155 , A61K31/4178 , A61K31/4184 , A61K31/421 , A61K31/422 , A61K31/427 , A61K31/4439 , A61K31/454 , A61K31/496 , A61K31/506 , A61K31/5377 , A61K31/635 , C07D209/42 , C07D403/12 , C07D405/12 , C07D409/12 , C07D413/12
摘要: The use of a 3-substituted indole compound of formula (I) or a pharmaceutically acceptable salt, amide or ester thereof; X is CH2 or SO2 and R1, R2, R3, R4, R5, R6 and R7 are certain specified organic moieties, for use in the preparation of a medicament for the inhibition of monocyte chemoattractant protein-1 and/or RANTES induced chemotaxis. Pharmaceutical compositions containing certain compounds of formula (I) and novel compounds of formula (I) are also described and claimed.
摘要翻译: 使用式(I)的3-取代吲哚化合物或其药学上可接受的盐,酰胺或酯; X是CH 2或SO 2,R 1,R 2,R 3,R 4,R 5,R 6和R 7是某些指定的有机部分,用于 制备用于抑制单核细胞趋化蛋白-1和/或RANTES诱导的趋化性的药物。 还描述和要求保护含有某些式(I)化合物和式(I)的新化合物的药物组合物。
-
公开(公告)号:US5563141A
公开(公告)日:1996-10-08
申请号:US218174
申请日:1994-03-28
申请人: Michael G. Wayne , Michael J. Smithers , John W. Rayner , Alan W. Faull , Robert J. Pearce , Andrew G. Brewster , Richard E. Shute , Stuart D. Mills , Peter W. R. Caulkett
发明人: Michael G. Wayne , Michael J. Smithers , John W. Rayner , Alan W. Faull , Robert J. Pearce , Andrew G. Brewster , Richard E. Shute , Stuart D. Mills , Peter W. R. Caulkett
IPC分类号: A61K31/44 , A61K31/4402 , A61K31/4406 , A61K31/4409 , A61K31/4418 , A61K31/4427 , A61K31/445 , A61K31/4545 , A61K31/47 , A61K31/505 , A61K31/5377 , A61P7/02 , A61P43/00 , C07D213/74 , C07D213/81 , C07D215/14 , C07D215/42 , C07D239/42 , C07D401/04 , C07D401/12 , C07D401/14 , C07D405/12 , C07D521/00 , A61K31/495 , C07D401/00 , C07D403/00 , C07D405/00
CPC分类号: C07D213/74 , C07D213/81 , C07D215/42 , C07D239/42 , C07D401/04 , C07D401/12 , C07D401/14 , C07D405/12
摘要: A compound of the general formula(M.sup.1).sub.n --Q--(M.sup.2).sub.1-n --L--A Iwherein:n is 0 or 1;M.sup.1 is an amino group;Q is an aromatic heterocyclic group containing a basic nitrogen atom;M.sup.2 is an imino group;L is a template group; andA is an acidic group, or an ester or amide derivative thereof, or a sulphonamide group;and pharmaceutically acceptable salts and pro-drugs thereof, for use in the treatment of a disease in which platelet aggregation mediated by the binding of adhesion molecules to GPIIb-IIIa is involved. Novel compounds are also disclosed.
摘要翻译: 通式(M1)n-Q-(M2)1-n-L-1的化合物,其中n为0或1; M1是氨基; Q是含有碱性氮原子的芳香族杂环基; M2是亚氨基; L是模板组; A是酸性基团,或其酯或酰胺衍生物或磺酰胺基团; 和其药学上可接受的盐和前药,用于治疗由粘附分子与GPIIb-IIIa的结合介导的血小板聚集的疾病。 还公开了新的化合物。
-
公开(公告)号:US5556977A
公开(公告)日:1996-09-17
申请号:US218171
申请日:1994-03-28
申请人: Michael G. Wayne , Michael J. Smithers , John W. Rayner , Alan W. Faull , Robert J. Pearce , Andrew G. Brewster , Richard E. Shute , Sturat D. Mills , Peter W. R. Caulkett
发明人: Michael G. Wayne , Michael J. Smithers , John W. Rayner , Alan W. Faull , Robert J. Pearce , Andrew G. Brewster , Richard E. Shute , Sturat D. Mills , Peter W. R. Caulkett
IPC分类号: A61K31/44 , A61K31/4409 , A61K31/4418 , A61P7/02 , C07D213/74 , C07D401/00
CPC分类号: C07D213/74
摘要: Compounds of formula I ##STR1## and metabolically labile esters and amides thereof, and pharmaceutically acceptable salts thereof, in which R.sup.13, M.sup.2, X.sup.1, Z.sup.1, Z.sup.1a, X.sup.2 and A.sup.1 have the meanings given in the specification. The compounds are useful as inhibitors of the binding of fibrinogen to glycoprotein IIb/IIIa. Intermediates are also disclosed.
摘要翻译: 式I的化合物(I)及其代谢不稳定的酯和酰胺及其药学上可接受的盐,其中R13,M2,X1,Z1,Z1a,X2和A1具有说明书中给出的含义。 该化合物可用作纤维蛋白原与糖蛋白IIb / IIIa结合的抑制剂。 还公开了中间体。
-
公开(公告)号:US5053415A
公开(公告)日:1991-10-01
申请号:US424611
申请日:1989-10-20
IPC分类号: A61K31/357 , A61K31/44 , A61K31/4427 , A61K31/443 , A61K31/4433 , A61P9/00 , A61P9/08 , A61P9/10 , A61P11/08 , A61P29/00 , C07D405/00 , C07D405/04 , C07D405/14 , C07D407/14 , C07D409/00 , C07D409/14
CPC分类号: C07D405/04 , C07D407/14 , C07D409/14
摘要: The invention concerns novel, pharmaceutically useful 1,3-dioxane alkenoic acid derivatives of the formula I containing a pyridyl moiety at position 4 of the dioxane ring and in which the groups at positions 2, 4 and 5 have cis-relative stereochemistry, X is hydrogen, alkoxy or hydroxy, Y is vinylene, n is 1 or 2, A.sup.1 is alkylene, the substituents R.sup.1 and R.sup.2 at position 2 of the dioxane ring have a variety of values defined hereinafter, and R.sup.4 is hydroxy, a physiologically acceptable alcohol residue or alkanesulphonamido, and the pharmaceutically acceptable salts thereof. The invention also includes processes for the manufacture and use of the acid derivatives as well as pharmaceutical compositions for therapeutic use in one or more of a variety of diseases such as ischaemic heart disease, cerebrovascular disease, asthmatic disease and/or inflammatory disease.
-
公开(公告)号:US5612373A
公开(公告)日:1997-03-18
申请号:US266375
申请日:1994-06-27
申请人: Andrew G. Brewster , Peter W. R. Caulkett , Alan W. Faull , Robert J. Pearce , Richard E. Shute
发明人: Andrew G. Brewster , Peter W. R. Caulkett , Alan W. Faull , Robert J. Pearce , Richard E. Shute
IPC分类号: C07D295/14 , A61K31/195 , A61K31/215 , A61K31/445 , A61K31/4465 , A61P7/02 , A61P9/08 , A61P9/10 , A61P25/04 , A61P43/00 , C07C243/38 , C07C257/18 , C07D211/34 , C07D211/42 , C07D211/46 , C07D211/62 , C07D295/20 , C07D295/215 , A61K31/165 , A61K31/275 , C07C255/46
CPC分类号: C07D295/215 , C07C243/38 , C07C257/18 , C07D211/34 , C07D211/46 , C07D211/62
摘要: The invention concerns acid derivatives of formula IR.sup.1 --CON(R.sup.2)--N(R.sup.3)CO--X.sup.1 --Q--X.sup.2 --GIand pharmaceutically acceptable metabolically labile esters or amides thereof, and pharmaceutically acceptable salts thereof, in which R.sup.1, R.sup.2, R.sup.3, X.sup.1, Q, X.sup.2 and G have the meanings given in the specification. The invention also concerns processes for the preparation of the acid derivatives of formula I, pharmaceutical compositions containing them and their use as inhibitors of the binding of fibrinogen to glycoprotein IIb/IIIa.
摘要翻译: 本发明涉及式IR1-CON(R2)-N(R3)CO-X1-Q-X2-GI和其药学上可接受的代谢不稳定酯或酰胺及其药学上可接受的盐的酸衍生物,其中R1,R2,R3, X1,Q,X2和G具有说明书中给出的含义。 本发明还涉及制备式I的酸衍生物的方法,含有它们的药物组合物及其作为纤维蛋白原与糖蛋白IIb / IIIa结合的抑制剂的用途。
-
公开(公告)号:US5401849A
公开(公告)日:1995-03-28
申请号:US78658
申请日:1993-06-21
IPC分类号: C07D405/04 , C07D405/14
CPC分类号: C07D405/04 , C07D405/14
摘要: The invention concerns pharmaceutically useful 1,3-dioxane alkenoic acid derivatives of formula VII and formula XI containing a pyridyl moiety at position 4 of the dioxane ring and in which the groups at positions 2, 4 and 5 have cis-relative stereochemistry, wherein X is hydrogen, alkoxy or hydroxy, Y is vinylene, n is 1 or 2, A.sup.1 is alkylene, R.sup.1 is a variety of substituents defined hereinafter, Ra and Rb are independently methyl or ethyl, R.sup.2 is hydroxy, a physiologically acceptable alcohol residue or alkanesulphonamido, and the pharmaceutically acceptable salts thereof.
摘要翻译: 本发明涉及式VII和式XI的药学上有用的1,3-二恶烷烯酸衍生物,其在二恶烷环的4位含有吡啶基部分,其中2,4和5位的基团具有顺式相对立体化学,其中X 是氢,烷氧基或羟基,Y是亚乙烯基,n是1或2,A1是亚烷基,R1是下文定义的各种取代基,R a和R b独立地是甲基或乙基,R 2是羟基,生理上可接受的醇残基或烷基磺酰胺 ,及其药学上可接受的盐。
-
公开(公告)号:US5166213A
公开(公告)日:1992-11-24
申请号:US310235
申请日:1989-02-14
IPC分类号: A61K31/44 , A61K31/443 , A61P7/02 , A61P9/00 , A61P9/08 , A61P9/10 , A61P9/12 , A61P11/00 , A61P11/08 , A61P29/00 , A61P43/00 , C07D405/04 , C07D405/14
CPC分类号: C07D405/04 , C07D405/14
摘要: The invention concerns novel, pharmaceutically useful 1,3-dioxane alkenoic acid derivatives of the formula I containing a pyridyl moiety at position 4 of the dioxane ring and in which the groups at positions 2, 4 and 5 have cis-relative stereochemistry, X is hydrogen, alkoxy or hydroxy, Y is vinylene, n is 1 or 2, A.sup.1 is alkylene, R.sup.1 is a variety of substituents defined hereinafter, and R.sup.2 is hydroxy, a physiologically acceptable alcohol residue or alkanesulphonamido, and the pharmaceutically acceptable salts thereof. The invention also includes processes for the manufacture and use of the acid derivatives as well as pharmaceutical compositions for therapeutic use in one or more of a variety of diseases such as ischaemic heart disease, cerebrovascular disease, asthmatic disease and/or inflammatory disease.
-
-
-
-
-
-
-
-
-